Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDSBusiness Wire • 10/24/23
New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIVBusiness Wire • 10/20/23
Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of ComorbiditiesBusiness Wire • 10/19/23
Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead StockInvestors Business Daily • 10/18/23
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose ProgramBusiness Wire • 10/18/23
Gilead to pay Assembly Bio an initial $100 million as part of 12-year partnership to develop antiviral drugsMarket Watch • 10/17/23
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral DiseasesBusiness Wire • 10/17/23
Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023Business Wire • 10/16/23
Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023Business Wire • 10/16/23
Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023Business Wire • 10/12/23
If You Purchased Brand or Generic Truvada or Atripla Directly From the Manufacturer, You May Receive a Payment From a Class Action Settlement; Gilead Agreed to Pay $246,750,000 Into a Settlement Fund, Announces Roberts Law Firm, PC and NastLaw LLCBusiness Wire • 10/09/23
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023Business Wire • 10/03/23